ibbtec@unican.es

 

Skip Navigation LinksEspañol (España) > Investigación > Publicaciones > Detalle publicación

 

 

New strategies in the search of antipsychotic drugs. New strategies in the search of antipsychotic drugs. Adell A. (2010) Curr. Pharm. Des. 16: 486-487. 2009-12-31T23:00:00Z<div class="page" title="Page 1" style="color:#000000;text-align:justify;"><div class="layoutArea"><div class="column"><p><span class="ms-rteThemeFontFace-1 ms-rteFontSize-2"><strong>Abstract</strong></span></p><p><span class="ms-rteThemeFontFace-1 ms-rteFontSize-2">Schizophrenia is a chronic, severe, and disabling brain disorder characterized by a profound disruption of perception, cognition, and emotion. The condition affects approximately 1% of the population and is thought to be the result of genetic vulnerability and environmental influences. The symptoms of schizophrenia fall into three main categories, i.e. positive symptoms (hallucinations, delusions), negative symptoms (apathy, lack of emotion) and cognitive symptoms (problems with attention, certain types of memory, and executive functions). Antipsychotic medications available effectively alleviate the positive symptoms of schizophrenia. However, negative symptoms and cognitive deficits remain poorly treated and are considered to belong to a core syndrome in schizophrenia. For this reason, investigators are developing more effective medications and using new research tools to understand the causes of schizophrenia and to find better ways to prevent and treat it.</span></p><p><span class="ms-rteThemeFontFace-1 ms-rteFontSize-2">The present issue provides a state of the art review of some of these new pharmacological approaches in this rapidly expanding area.</span></p></div></div></div><p>​<span class="ms-rteFontSize-3" style="margin:0px;padding:0px;border:0px;font-stretch:inherit;line-height:inherit;font-family:"yanone kaffeesatz";vertical-align:baseline;color:#474f51;text-align:justify;background-color:#ffffff;">[</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/20236076" style="color:#ed391b;margin:0px;padding:0px;border:0px;font-stretch:inherit;font-size:18px;line-height:1.6;font-family:"yanone kaffeesatz";vertical-align:baseline;text-align:justify;background-color:#ffffff;"><span class="ms-rteFontSize-3" style="margin:0px;padding:0px;border:0px;font-style:inherit;font-stretch:inherit;line-height:inherit;font-family:inherit;vertical-align:baseline;">PubMed</span></a><span class="ms-rteFontSize-3" style="margin:0px;padding:0px;border:0px;font-stretch:inherit;line-height:inherit;font-family:"yanone kaffeesatz";vertical-align:baseline;color:#474f51;text-align:justify;background-color:#ffffff;">]</span><br></p>19
IBBTEC

Instituto de Biomedicina y Biotecnología de Cantabria.
PCTCAN - Cl. Albert Einstein, 22
39011 Santander

Inicio de sesión